BioSig Technologies, Inc. is a prominent medical technology company that specializes in delivering unrivaled precision and accuracy in intracardiac signal visualization. In recent developments, the company has made significant progress in the research and development of an artificial intelligence (AI) medical device platform. This article provides an update on BioSig’s endeavors and collaborations in this field.
Inclusion in Nvidia’s Inception Partnership Program
In an exciting announcement on July 20, 2023, BioSig AI Sciences, Inc. (BAIS), a majority-owned subsidiary of BioSig, was selected to participate in Nvidia’s prestigious Inception partnership program. This partnership opens up new avenues for engineering and technology support, providing BioSig’s team with access to invaluable resources.
Seed round funding for BAIS
On July 23, 2023, BAIS successfully closed its seed round of funding, securing an impressive $2.2 million. This funding round enabled BAIS to solidify its position in the medical technology market, with the majority-owned subsidiary now valued at an impressive $15 million. This robust foundation enables the subsidiary to forge ahead with innovative research and development efforts.
Engaging with hospital customers
Within a month of closing the initial funding round, BAIS has been actively engaging with numerous hospital customers at the highest levels of leadership. These interactions have been fruitful, as BAIS has identified multiple opportunities to introduce its proprietary AI platform into the market. The enthusiasm displayed by these institutions underscores the potential value that BAIS’s technology can bring to the medical sector.
Collaboration Agreement with a Global Technology Organization
BioSig recently signed a significant collaboration agreement with a leading global technology organization. This partnership focuses on building essential data infrastructure that will facilitate the scaling of BioSig’s AI platform in high-volume and data-intensive hospital centers. By joining forces with this partner, BioSig aims to optimize the platform’s capabilities and ensure its seamless integration into healthcare ecosystems worldwide.
CEO Statement on Growth Opportunities
Kenneth Londoner, Chairman & CEO of BioSig, has expressed his excitement and confidence in the future of the company. With over 30 years of experience in the technology marketplace, Londoner acknowledges the unparalleled growth opportunities that lie ahead. This optimism stems from the relationships cultivated by BioSig and the increasing commercial placements of their PURE EP™ platform technology. Combined with external technology collaborations and internal capabilities, BioSig expects to demonstrate substantial progress not only in 2023 but also in the years to come.
Market outlook for AI in healthcare
According to a report by Data Bridge Market Research, the AI in healthcare market is projected to experience exponential growth in the coming years. In 2022, the market was valued at $9.6 billion, and by 2030, it is estimated to reach a staggering $272.9 billion, with a compound annual growth rate (CAGR) of 51.9%. This data underscores the immense potential for AI technology in revolutionizing healthcare delivery and improving patient outcomes.
Importance of entrepreneurial and agile market participants
Leading hospitals are actively seeking innovative and agile emerging market participants to test and adopt AI-based solutions. BioSig, with its expertise and dynamic approach, fits the mold of what these hospitals are looking for. The company’s commitment to developing cutting-edge technology aligns with the demands and aspirations of the healthcare industry, thus positioning BioSig favorably in this rapidly evolving landscape.
BioSig Technologies has made significant strides in advancing its AI medical device platform through strategic collaborations and securing substantial funding. The inclusion in Nvidia’s Inception partnership program, completion of a successful seed round, engagement with hospital customers, and collaboration with a global technology organization all contribute to BioSig’s trajectory towards becoming a key player in the medical technology sector. With the projected growth of AI in healthcare, BioSig is well-positioned to make a lasting impact in the industry, improving patient care and outcomes through innovative AI-driven solutions.